| Oncologic imaging end-points for the assessment of therapy response. | |
| | |
MedLine Citation:
|
PMID: 19149687 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Sophisticated clinical and diagnostic imaging modalities are critical for the detection, staging, treatment, and follow-up surveillance of cancer. Previously, uni- and bi-dimensional measurements of a tumor lesion were considered the "holy grail" of the assessment of tumor growth and provided imaging end-points for cytotoxic chemotherapeutic agents. With increasing understanding of cancer-related pathways and emerging discoveries of targeted signal transduction inhibitors for cancer treatment, novel pharmacodynamic endpoints of treatment efficacy are required. The innovations in medical imaging include computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), single photon emission tomography (SPECT), ultrasonography (US) and, mostly in the pre-clinical arena, optical imaging. While CT and MRI provide superb anatomic resolution, physiological changes in tumor microenvironment can be assessed by dynamic contrast enhanced MRI (DCE-MRI), metabolic endpoints can be established with PET and MRS protocol, and molecular biomarkers can be non-invasively followed up using PET and MRI-based molecular probes (and optical imaging mostly in pre-clinical setting). Novel protocols for improved spatial resolution, automated quantitative methods for anatomic assessment, and development of physiological, metabolic and molecular imaging probes are currently under investigation. The imaging future promises new avenues for exploration of physiological, metabolic, molecular and genetic events in the human body, performed non-invasively and in real time, using multi-modality imaging platforms. The aim of this article is to represent the available patents on imaging response assessment in oncology. |
| | |
Authors:
|
Natalie J Serkova; Kavita Garg; Erica L Bradshaw-Pierce |
Related Documents
:
|
18594327 - Adenoid cystic carcinoma of the trachea treated with pet-ct based intensity modulated r... 14736837 - Why most pet of lung and head-and-neck cancer will be pet/ct. 21049467 - The role of pet-ct scan with somatostatin analogue labelled with gallium-68 ((68)ga-dot... 18154677 - Combined approach of perioperative 18f-fdg pet/ct imaging and intraoperative 18f-fdg ha... 4010897 - Magnetic resonance imaging of acoustic neuromas. 21763477 - Development of micro-ct protocols for in vivo follow-up of mouse bone architecture with... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Recent patents on anti-cancer drug discovery Volume: 4 ISSN: 1574-8928 ISO Abbreviation: Recent Pat Anticancer Drug Discov Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-01-19 Completed Date: 2009-03-24 Revised Date: 2011-11-10 |
Medline Journal Info:
|
Nlm Unique ID: 101266081 Medline TA: Recent Pat Anticancer Drug Discov Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 36-53 Citation Subset: IM |
Affiliation:
|
Department of Anesthesiology, University of Colorado Cancer Center, Aurora, CO 80045, USA. Natalie.Serkova@ucdenver.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Diagnostic Imaging / methods* Humans Magnetic Resonance Imaging / methods Magnetic Resonance Spectroscopy / methods Neoplasms / blood supply, diagnosis*, metabolism, therapy Positron-Emission Tomography / methods Tomography, X-Ray Computed / methods |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.
Next Document: Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment str...